Hadassah

Israeli Biotech Co. Receives Major Grant to Further Develop Treatment for AMD

Wednesday, May 13 2015

To further develop its world-first, animal product-free stem cell treatment for age-related macular degeneration (AMD), Israel’s Cell Cure Neurosciences Ltd. has received a 6.24 million shekel (approximately $1.6 million dollar) grant from Israel's Office of the Chief Scientist (OCS).

A clinical trial using this product was initiated in February at the Hadassah Medical Organization, whose Prof. Benjamin Reubinoff, Chief Scientific Officer of Cell Cure and Director of Hadassah's Human Embryonic Stem Cell Research Center, and Prof. Eyal Banin, head of the Center for Retinal and Macular Degeneration, were instrumental in its development. The product, called OpRegen®, is a retinal pigment epithelial (RPE) cell formulation derived from human embryonic stem cells (hESCs), characterized by high purity and potency.

"We thank the Israel Office of the Chief Scientist for its commitment to innovation and for continuing support of Cell Cure and its development of a cell therapy-based treatment for a major disease of aging," said Charles Irving, PhD, Chief Executive Officer of Cell Cure.

"I join with Dr. Irving in thanking the OCS for its generous support in advancing pluripotent stem cell research into clinical applications," Prof. Reubinoff related.

The Phase I/IIa study of OpRegen® has been designed to provide preliminary, objective, functional and structural data on this cell transplantation's ability to slow the progression of geographic atrophy (dry-AMD), in addition to safety data. Dry-AMD severely impacts the quality of life of the elderly and there is as yet no approved therapy.

The clinical trial, involving four groups of patients, will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months. Details of the trial are available at https://clinicaltrials.gov/ct2/show/NCT02286089?term=OpRegen&rank=1

Dry AMD is the leading cause of visual impairment and blindness among the elderly in the US and other developed countries. While treatment options exist for the treatment of the wet form of AMD, 90 percent of all patients with AMD have the dry form. As Cell Cure's website explains: "The root cause of dry-AMD is believed to be the dysfunction of RPE cells. Therefore, one of the most exciting new therapeutic strategies for dry-AMD is the transplantation of healthy young RPE cells to support and replace those lost with age. Pluripotent stem cells, such as hESCs, can potentially provide a means of manufacturing such healthy RPE cells on an industrial scale."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jun 20 2017

Send in the Clowns: A Hadassah UK Dispatch

This week Hadassah UK (HUK) brought in one of the Hadassah Medical Organization's best and more unusual, head medical clown David Barashi (DuSH).

READ MORE ›
alt_text

Friday, Jun 16 2017

Hadassah’s Director General Receives Honorary PhD from Cyprus Medical School

For sharing his knowledge and experience with senior officials in the Cyprus medical system, Prof. Zeev Rotstein, Director General of the Hadassah Medical Organization, was awarded an honorary PhD from the St. George University of London’s Medical Program at the University of Nicosia Medical School in Cyprus.

READ MORE ›
alt_text

Thursday, Jun 8 2017

Hadassah Doctors Discover Bullet
in 12-Year-Old’s Arm

Muhammad Baduan, age 12, had been experiencing pain in his arm on and off for months. Hadassah Hospital Ein Kerem Emergency Room physicians put an end to the boy’s pain when they solved the mystery: Muhammad had a 22-millimeter bullet hidden in that arm--a bullet that had been shot into the air as part of a post-wedding ceremony celebration.

READ MORE ›
alt_text

Monday, Jun 5 2017

Hadassah Cutting-Edge Neuropsychiatrist Keynotes Alzheimer’s Conference

“The key is to give medicines much earlier--before the brain material has been destroyed by Alzheimer’s disease,” Dr. Shahar Arzy, head of the Hadassah Medical Organization’s Computational Neuropsychiatry Laboratory, told his audience at the Alzheimer’s Foundation of America (AFA)’s New York Educational Conference on May 5, 2017.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More